Please login to the form below
Digital intelligence blog
Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools
J&J collaborates on consumer health device accelerator
Partners with Shenzhen-based investor firm HAX
Johnson & Johnson is working with Shenzhen-based investor firm HAX on an accelerator programme for novel consumer health devices.
The firm's Johnson & Johnson Innovation arm will work with HAX on supporting start-ups that are developing technologies in areas such as skin care, baby care and wound care.
The world's largest hardware accelerator with bases in Silicon Valley and south east China, HAX has a specific health track within its Shenzhen hardware accelerator.
Companies that have successfully applied to its spring 2017 call for entries and are then co-selected by HAX and J&J will receive mentorship in business development and commercialization from Johnson & Johnson Innovation executives.
They will also, HAX said, learn how to align their products with Johnson & Johnson's consumer health care portfolio.
Featured jobs
- Experienced / Senior Medical Writer - Excellent Progression Oppo...
-
Excellent Salary and Benefits on offer
- Senior Account Manager / Account Director - MedComms - London
-
Highly competitive salary &package
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior / Principal Medical Writers wanted - MedComms - Various U...
-
Excellent Remuneration Packages
-
Senior Copywriter
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
-
Senior Medical Writer
-
Competitive salary plus benefits
- Editorial Assistants - Medical Communications agency - Cheshire
-
Excellent Remuneration Package
- Senior Medical Writer – Medical Communications – North West – In...
-
Excellent Remuneration Package
Subscribe to our email news alerts
- Novartis bags US okay for Lucentis follow-up Beovu in wet AMD
- GSK forms cell therapy R&D pact with star-studded biotech
- UCB gets bigger in rare diseases with $2.1bn purchase of Ra Pharma
- Merck seeks partner for disease-modifying osteoarthritis drug
- Bayer/J&J claim new FDA okay for clot drug Xarelto
- Allergan investors back AbbVie deal, but is a tax charge looming?
- What is changing in cardiovascular disease care?
- Tranexamic acid linked to lower death rate in some brain injury patients
- Horizon shares data on eye disease drug as FDA decision nears
- Allergan investors back AbbVie deal, but is a tax charge looming?
- Bayer/J&J claim new FDA okay for clot drug Xarelto
- 90TEN named Specialist Consultancy of the Year at 2019 PRWeek UK Awards
PMHub
Ashfield
Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...
Latest intelligence
- What is changing in cardiovascular disease care?
- Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
- PANDAS/PANS Awareness: A parent’s story
- To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
- Leading AstraZeneca’s return to growth in Europe
- PME talks to Iskra Reic, the company’s head of Europe and Canada...
Quick links
Infographics
